Aardvark Therapeutics, Inc.
AARD
$4.11
-$0.43-9.47%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -152.05% | -179.73% | -252.14% | -211.10% | -252.81% |
| Total Depreciation and Amortization | 121.05% | 125.00% | 153.13% | 169.57% | 190.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 437.80% | 231.91% | 90.80% | -34.60% | -44.10% |
| Change in Net Operating Assets | 838.92% | -77.37% | 27.00% | 122.97% | -172.73% |
| Cash from Operations | -125.96% | -199.51% | -291.53% | -259.87% | -321.55% |
| Capital Expenditure | 8.65% | 12.84% | 1.94% | -4.08% | -1,980.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 178.15% | -316.96% | -- | -- | -- |
| Cash from Investing | 178.00% | -313.96% | -83,263.11% | -117,364.29% | -2,492,240.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.50% | 27,501.20% | 54,056.80% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.64% | 28.55% | -64.70% | -78.19% | -- |
| Cash from Financing | -99.78% | 8.85% | 5.97% | 5.92% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.47% | -128.11% | -160.22% | -181.65% | 392.77% |